Journal
BLOOD
Volume 112, Issue 1, Pages 11-18Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-02-078170
Keywords
-
Categories
Funding
- Howard Hughes Medical Institute Funding Source: Medline
- NHLBI NIH HHS [HL89746, R01 HL072917, R01 HL089746, HL72917] Funding Source: Medline
Ask authors/readers for more resources
Discoveries during the past decade have revolutionized our understanding of idiopathic thrombotic thrombocytopenic purpura (TTP). Most cases in adults are caused by acquired autoantibodies that inhibit ADAMTS13, a metalloprotease that cleaves von Willebrand factor within nascent platelet-rich thrombi to prevent hemolysis, thrombocytopenia, and tissue infarction. Although approximately 80% of patients respond to plasma exchange, which removes autoantibody and replenishes ADAMTS13, one third to one half of survivors develop refractory or relapsing disease. Intensive immunosuppressive therapy with rituximab appears to be effective as salvage therapy, and ongoing clinical trials should determine whether adjuvant rituximab with plasma exchange also is beneficial at first diagnosis. A major unanswered question is whether plasma exchange is effective for the subset of patients with idiopathic TTP who do not have severe ADAMTS13 deficiency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available